Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Non-Current Assets (2016 - 2026)

Champions Oncology has reported Non-Current Assets over the past 16 years, most recently at $8.3 million for Q1 2026.

  • For Q1 2026, Non-Current Assets fell 24.41% year-over-year to $8.3 million; the TTM value through Jan 2026 reached $36.6 million, down 20.99%, while the annual FY2025 figure was $10.0 million, 20.07% down from the prior year.
  • Non-Current Assets for Q1 2026 was $8.3 million at Champions Oncology, down from $8.8 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $16.0 million in Q3 2022 and troughed at $8.3 million in Q1 2026.
  • A 5-year average of $12.9 million and a median of $13.6 million in 2024 define the central range for Non-Current Assets.
  • Biggest five-year swings in Non-Current Assets: surged 39.57% in 2022 and later decreased 24.41% in 2026.
  • Year by year, Non-Current Assets stood at $15.8 million in 2022, then dropped by 9.39% to $14.3 million in 2023, then dropped by 21.86% to $11.2 million in 2024, then fell by 20.85% to $8.8 million in 2025, then fell by 6.43% to $8.3 million in 2026.
  • Business Quant data shows Non-Current Assets for CSBR at $8.3 million in Q1 2026, $8.8 million in Q4 2025, and $9.5 million in Q3 2025.